Pioneers in Oral Microbiome Since 2013

Home/Bluestone Pharma 

Bluestone Pharma in Short

We are at the forefront of oral microbiome research, innovation, and product development, having successfully established a robust global market presence.

Our mission is to deliver groundbreaking product formulations targeting the oral microbiome, distinguished by:

• Developed by oral microbiome experts
• Proprietary briquetting lozenge technology 
• Significant investment in clinical evidence

We are dedicated to empowering our partners with a competitive edge, ensuring their success and market leadership.

 

2013

Founded

6

Categories

25

Countries

40

Team

A Decade of Excellence in Oral Microbiome Innovation

2013
  • BSP foundation and pioneering the oral probiotic market
  • Launch of the World’s 1st oral probiotic in EU: "Bactoblis®"
2015

Bactoblis® awarded Vitafood’s Best Finished Product of the Year.

2019

Bactoblis® referenced in probiotic guidelines

2021

Bactoblis® referenced in medical guidelines for Tonsillopharyngitis

2022
  • Strategic partnership with Chr. Hansen for dual-probiotic blends
  • Bactoblis® category leader in GE, PL, CH, IT, RU, CZ, and RO.
  • Bactoblis® 30th clinical publication
  • Bactoblis® awarded Best Probiotic Product
2023
  • International expansion into China
  • Launch of  ImmuneBioflora® and Bactoblis® Adult (Dual- probiotic blends)
2024
  • Acquisition of Medico Domus production site and €3M invested in facility expansion
  • Acquisition of Probionet China R&D and sales network
  • Pipeline expansion: EGY, BRZ, IND
  • Launch of the 1st oral probiotic in oil drop delivery format
2025
  • Bactoblis® expert consensus published in international medical journal: Frontiers in Pediatrics 

Get in touch

Complete the following contact form and we will get back to you as soon as possible.